Bio-Techne Corp (NASDAQ: TECH) is a life science tools company that develops and manufactures biological reagents, protein analysis instruments, and diagnostic products for research, diagnostics, and cell and gene therapy applications. It generates revenue through transactional product sales across two segments: Protein Sciences (approximately 72% of the business per the FY2025 10-K filing) and Diagnostics and Spatial Biology. The company is headquartered in Minneapolis, Minnesota, was founded in 1976 as Research and Diagnostic Systems, Inc., and became publicly traded in 1985 through a merger with Techne Corporation. It operates globally across North America, Europe, and other international markets. Key brands include R&D Systems, ProteinSimple, Exosome Diagnostics, and Asuragen. Customers span academic researchers, pharmaceutical and biotech companies, contract research organizations, and clinical diagnostic manufacturers. Many diagnostic reagent products are sold on an OEM basis, manufactured to customer specifications.

Revenue model

Transactional product sales of biological reagents, protein analysis instruments, immunoassay kits, and diagnostic controls and calibrators. A portion of the Diagnostics segment sells reagents on an OEM basis, custom-manufactured to customer diagnostic assay specifications. The company also offers laboratory-developed diagnostic tests, such as ExoDx Prostate, as a service.

Products and services

Protein Sciences segment: high-quality biological reagents (branded R&D Systems), automated and manual protein analysis instruments including automated western blotting and multiplexed ELISA platforms (branded ProteinSimple), and bioactive reagents for cell and gene therapy manufacturing. Diagnostics and Spatial Biology segment: diagnostic controls, calibrators, and reagents for hematology, blood chemistry, coagulation, and other clinical applications; exosome-based liquid biopsy assays including ExoDx Prostate urine-based prostate cancer detection test and ExoTRU kidney transplant rejection test (licensed exclusively to Thermo Fisher Scientific); genetic carrier screening, oncology diagnostics, and molecular controls under the Asuragen brand; and spatial genomic and tissue in-situ hybridization instrumentation.

Customers and end markets

Academic and government research institutions, pharmaceutical and biotechnology companies, contract research organizations, diagnostic and companion diagnostic developers, cell and gene therapy manufacturers, and clinical diagnostic instrument makers purchasing OEM reagents. End markets include life science research, oncology diagnostics, molecular diagnostics, spatial biology, and regulated clinical diagnostics.

Value-chain role

Upstream supplier of research-grade and diagnostic-grade biological reagents, analytical instruments, and assay kits. Sits between raw material inputs and end-user researchers or clinical diagnostic instrument manufacturers. Sells direct through an internal sales force and through distribution channels globally. Also acts as OEM reagent manufacturer for diagnostic instrument companies.

Geographic exposure

Global operations with headquarters in Minneapolis, Minnesota. Offices in multiple locations across North America, Europe, and other international regions, as disclosed in the FY2025 10-K (filed 2025-08-22).

Source: SEC 10-K, filed 2025-08-22

Industry: Biological Products, (No Diagnostic Substances) Peers: Avantor Inc Bio Rad Laboratories Inc Bruker Corp Charles River Laboratories International Inc Revvity Inc Maravai LifeSciences Holdings Inc Repligen Corp Thermo Fisher Scientific Inc West Pharmaceutical Services Inc Waters Corp